Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1123

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 4
Chunk 1123
---
117 
  
    Cash paid During the Year for Income Taxes 
    $2,000  
    $1,000 

    NONCASH INVESTING/FINANCING ACTIVITIES 

    Conversion of Debt into Common Stock 
    $-  
    $7,989,598 
  
    Conversion of Debt into Series A Preferred Stock 
    $-  
    $10,128,500 
  
    Conversion of Series A Preferred Stock into Common Stock 
    $290,601  
    $270,460 
  
    Capitalized Share-Based Payments to Vendors 
    $26,325  
    $4,916,555 
  
    Fair Value of Warrants Issued to Underwriters 
    $71,364  
    $301,416 
  
    Reclassification of Liability-classified Warrants to Equity-classified 
    $-  
    $838,748 
  
    Additions to ROU Assets for Lease Renewal 
    $-  
    $50,922 
  
    Additions to Lease Liabilities for Lease Renewal 
    $-  
    $50,570 
  
    Debt Discount Recorded in Connection with Derivative Liabilities 
    $-  
    $650,000 
  
    Stock Issued for Payment of Deferred Compensation 
    $-  
    $520,000 
  
    Stock Issued for Acquisition of Intangibles 
    $-  
    $33,895 

See accompanying notes to these consolidated
financial statements which are an integral part of these consolidated financial statements.

F-7

60 DEGREES PHARMACEUTICALS,
INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. NATURE OF OPERATIONS

60 Degrees Pharmaceuticals, Inc. was incorporated
in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability
company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively
as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that
specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA
approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018.